Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world
Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola‐BR) was approved for treatment of transplant‐ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data eva...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2022-08, Vol.109 (2), p.162-165 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 165 |
|---|---|
| container_issue | 2 |
| container_start_page | 162 |
| container_title | European journal of haematology |
| container_volume | 109 |
| creator | Vodicka, Prokop Benesova, Katerina Janikova, Andrea Prochazka, Vit Belada, David Mocikova, Heidi Steinerova, Katerina Duras, Juraj Karban, Josef Hanackova, Veronika Sykorova, Alice Obr, Ales Trneny, Marek |
| description | Objectives
Polatuzumab vedotin with bendamustine and rituximab (Pola‐BR) was approved for treatment of transplant‐ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed.
Methods
We analyzed 21 patients with R/R DLBCL to determine real‐life efficacy and safety of Pola‐BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066).
Results
Median overall survival was 8.7 months, and progression‐free survival 3.8 months. The overall response rate was 33%. Grade 3–4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR‐T therapy in 19%.
Conclusion
Although the outcome of patients is worse than in GO29365 trial, the use of Pola‐BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant‐ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR‐T therapy. |
| doi_str_mv | 10.1111/ejh.13784 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2659228132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2659228132</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2834-3ec2fae4bdd3c2d5b3b3464efcde727ced6c6e44df71672d2d69e7c08186101f3</originalsourceid><addsrcrecordid>eNp10ctu1DAUBmALUdGhsOAFkCU2sEjHtzjJklYtpaoEC1hHjn3CZOTEwReGYdU1K56RJ8HptCyQ8MaS9fnX0fkRekHJKc1nDdvNKeVVLR6hFZWEFESS5jFakYawQghBj9HTELaEENbQ6gk65mVJWDYr9POjsyqmH2lUHf4GxsVhwrNNAXcwGTWmkB8Aq8lgP8T0fVjcQlQcYIoB74a4wR6smgOYtYfeKx2d32Mz9H0KgK3yXwCf_b79pcFabPfjvHGjWkLiBvJXZfHOeWueoaNe2QDP7-8T9Pny4tP5VXHz4d3787c3hWY1FwUHzXoFojOGa2bKjndcSAG9NlCxSoORWoIQpq-orJhhRjZQaVLTWlJCe36CXh9yZ---JgixHYewzKYmcCm0TJYNYzXlLNNX_9CtS37K02VVl5yUsl7Um4PS3oWQV9DOPu_J71tK2qWgNhfU3hWU7cv7xNSNYP7Kh0YyWB_AbrCw_39Se3F9dYj8A7X5nd0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685305682</pqid></control><display><type>article</type><title>Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world</title><source>Wiley Journals</source><creator>Vodicka, Prokop ; Benesova, Katerina ; Janikova, Andrea ; Prochazka, Vit ; Belada, David ; Mocikova, Heidi ; Steinerova, Katerina ; Duras, Juraj ; Karban, Josef ; Hanackova, Veronika ; Sykorova, Alice ; Obr, Ales ; Trneny, Marek</creator><creatorcontrib>Vodicka, Prokop ; Benesova, Katerina ; Janikova, Andrea ; Prochazka, Vit ; Belada, David ; Mocikova, Heidi ; Steinerova, Katerina ; Duras, Juraj ; Karban, Josef ; Hanackova, Veronika ; Sykorova, Alice ; Obr, Ales ; Trneny, Marek</creatorcontrib><description>Objectives
Polatuzumab vedotin with bendamustine and rituximab (Pola‐BR) was approved for treatment of transplant‐ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed.
Methods
We analyzed 21 patients with R/R DLBCL to determine real‐life efficacy and safety of Pola‐BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066).
Results
Median overall survival was 8.7 months, and progression‐free survival 3.8 months. The overall response rate was 33%. Grade 3–4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR‐T therapy in 19%.
Conclusion
Although the outcome of patients is worse than in GO29365 trial, the use of Pola‐BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant‐ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR‐T therapy.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.13784</identifier><identifier>PMID: 35502609</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>B-cell lymphoma ; DLBCL ; Neutropenia ; Patients ; Peripheral neuropathy ; polatuzumab vedotin ; real world ; Rituximab ; Thrombocytopenia ; Toxicity</subject><ispartof>European journal of haematology, 2022-08, Vol.109 (2), p.162-165</ispartof><rights>2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2834-3ec2fae4bdd3c2d5b3b3464efcde727ced6c6e44df71672d2d69e7c08186101f3</citedby><cites>FETCH-LOGICAL-c2834-3ec2fae4bdd3c2d5b3b3464efcde727ced6c6e44df71672d2d69e7c08186101f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.13784$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.13784$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35502609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vodicka, Prokop</creatorcontrib><creatorcontrib>Benesova, Katerina</creatorcontrib><creatorcontrib>Janikova, Andrea</creatorcontrib><creatorcontrib>Prochazka, Vit</creatorcontrib><creatorcontrib>Belada, David</creatorcontrib><creatorcontrib>Mocikova, Heidi</creatorcontrib><creatorcontrib>Steinerova, Katerina</creatorcontrib><creatorcontrib>Duras, Juraj</creatorcontrib><creatorcontrib>Karban, Josef</creatorcontrib><creatorcontrib>Hanackova, Veronika</creatorcontrib><creatorcontrib>Sykorova, Alice</creatorcontrib><creatorcontrib>Obr, Ales</creatorcontrib><creatorcontrib>Trneny, Marek</creatorcontrib><title>Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives
Polatuzumab vedotin with bendamustine and rituximab (Pola‐BR) was approved for treatment of transplant‐ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed.
Methods
We analyzed 21 patients with R/R DLBCL to determine real‐life efficacy and safety of Pola‐BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066).
Results
Median overall survival was 8.7 months, and progression‐free survival 3.8 months. The overall response rate was 33%. Grade 3–4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR‐T therapy in 19%.
Conclusion
Although the outcome of patients is worse than in GO29365 trial, the use of Pola‐BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant‐ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR‐T therapy.</description><subject>B-cell lymphoma</subject><subject>DLBCL</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Peripheral neuropathy</subject><subject>polatuzumab vedotin</subject><subject>real world</subject><subject>Rituximab</subject><subject>Thrombocytopenia</subject><subject>Toxicity</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10ctu1DAUBmALUdGhsOAFkCU2sEjHtzjJklYtpaoEC1hHjn3CZOTEwReGYdU1K56RJ8HptCyQ8MaS9fnX0fkRekHJKc1nDdvNKeVVLR6hFZWEFESS5jFakYawQghBj9HTELaEENbQ6gk65mVJWDYr9POjsyqmH2lUHf4GxsVhwrNNAXcwGTWmkB8Aq8lgP8T0fVjcQlQcYIoB74a4wR6smgOYtYfeKx2d32Mz9H0KgK3yXwCf_b79pcFabPfjvHGjWkLiBvJXZfHOeWueoaNe2QDP7-8T9Pny4tP5VXHz4d3787c3hWY1FwUHzXoFojOGa2bKjndcSAG9NlCxSoORWoIQpq-orJhhRjZQaVLTWlJCe36CXh9yZ---JgixHYewzKYmcCm0TJYNYzXlLNNX_9CtS37K02VVl5yUsl7Um4PS3oWQV9DOPu_J71tK2qWgNhfU3hWU7cv7xNSNYP7Kh0YyWB_AbrCw_39Se3F9dYj8A7X5nd0</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Vodicka, Prokop</creator><creator>Benesova, Katerina</creator><creator>Janikova, Andrea</creator><creator>Prochazka, Vit</creator><creator>Belada, David</creator><creator>Mocikova, Heidi</creator><creator>Steinerova, Katerina</creator><creator>Duras, Juraj</creator><creator>Karban, Josef</creator><creator>Hanackova, Veronika</creator><creator>Sykorova, Alice</creator><creator>Obr, Ales</creator><creator>Trneny, Marek</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202208</creationdate><title>Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world</title><author>Vodicka, Prokop ; Benesova, Katerina ; Janikova, Andrea ; Prochazka, Vit ; Belada, David ; Mocikova, Heidi ; Steinerova, Katerina ; Duras, Juraj ; Karban, Josef ; Hanackova, Veronika ; Sykorova, Alice ; Obr, Ales ; Trneny, Marek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2834-3ec2fae4bdd3c2d5b3b3464efcde727ced6c6e44df71672d2d69e7c08186101f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>B-cell lymphoma</topic><topic>DLBCL</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Peripheral neuropathy</topic><topic>polatuzumab vedotin</topic><topic>real world</topic><topic>Rituximab</topic><topic>Thrombocytopenia</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vodicka, Prokop</creatorcontrib><creatorcontrib>Benesova, Katerina</creatorcontrib><creatorcontrib>Janikova, Andrea</creatorcontrib><creatorcontrib>Prochazka, Vit</creatorcontrib><creatorcontrib>Belada, David</creatorcontrib><creatorcontrib>Mocikova, Heidi</creatorcontrib><creatorcontrib>Steinerova, Katerina</creatorcontrib><creatorcontrib>Duras, Juraj</creatorcontrib><creatorcontrib>Karban, Josef</creatorcontrib><creatorcontrib>Hanackova, Veronika</creatorcontrib><creatorcontrib>Sykorova, Alice</creatorcontrib><creatorcontrib>Obr, Ales</creatorcontrib><creatorcontrib>Trneny, Marek</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vodicka, Prokop</au><au>Benesova, Katerina</au><au>Janikova, Andrea</au><au>Prochazka, Vit</au><au>Belada, David</au><au>Mocikova, Heidi</au><au>Steinerova, Katerina</au><au>Duras, Juraj</au><au>Karban, Josef</au><au>Hanackova, Veronika</au><au>Sykorova, Alice</au><au>Obr, Ales</au><au>Trneny, Marek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2022-08</date><risdate>2022</risdate><volume>109</volume><issue>2</issue><spage>162</spage><epage>165</epage><pages>162-165</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives
Polatuzumab vedotin with bendamustine and rituximab (Pola‐BR) was approved for treatment of transplant‐ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed.
Methods
We analyzed 21 patients with R/R DLBCL to determine real‐life efficacy and safety of Pola‐BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066).
Results
Median overall survival was 8.7 months, and progression‐free survival 3.8 months. The overall response rate was 33%. Grade 3–4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR‐T therapy in 19%.
Conclusion
Although the outcome of patients is worse than in GO29365 trial, the use of Pola‐BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant‐ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR‐T therapy.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35502609</pmid><doi>10.1111/ejh.13784</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2022-08, Vol.109 (2), p.162-165 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2659228132 |
| source | Wiley Journals |
| subjects | B-cell lymphoma DLBCL Neutropenia Patients Peripheral neuropathy polatuzumab vedotin real world Rituximab Thrombocytopenia Toxicity |
| title | Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A53%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polatuzumab%20vedotin%20plus%20bendamustine%20and%20rituximab%20in%20patients%20with%20relapsed/refractory%20diffuse%20large%20B%E2%80%90cell%20lymphoma%20in%20the%20real%20world&rft.jtitle=European%20journal%20of%20haematology&rft.au=Vodicka,%20Prokop&rft.date=2022-08&rft.volume=109&rft.issue=2&rft.spage=162&rft.epage=165&rft.pages=162-165&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.13784&rft_dat=%3Cproquest_cross%3E2659228132%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685305682&rft_id=info:pmid/35502609&rfr_iscdi=true |